Srikripa Devarakonda
Stock Analyst at Truist Securities
(3.11)
# 1,285
Out of 5,046 analysts
73
Total ratings
47.69%
Success rate
1.54%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Reiterates: Hold | $79 → $93 | $93.48 | -0.51% | 12 | Oct 29, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $76 → $88 | $78.62 | +11.93% | 3 | Oct 28, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $54 → $44 | $29.62 | +48.55% | 5 | Oct 20, 2025 | |
| VTRS Viatris | Initiates: Buy | $15 | $10.36 | +44.79% | 1 | Oct 15, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | $50 | $21.96 | +127.69% | 1 | Oct 15, 2025 | |
| MDGL Madrigal Pharmaceuticals | Initiates: Buy | $580 | $418.90 | +38.46% | 1 | Oct 15, 2025 | |
| TERN Terns Pharmaceuticals | Initiates: Buy | $20 | $8.26 | +142.13% | 1 | Oct 15, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $53 → $68 | $61.84 | +9.96% | 4 | Sep 30, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $940 → $812 | $651.80 | +24.58% | 8 | Aug 11, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $21 → $11 | $10.14 | +8.48% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $199 | $154.27 | +28.99% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $15.22 | +64.26% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,029 → $1,038 | $862.86 | +20.30% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $211 → $217 | $218.04 | -0.48% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $32 | $24.65 | +29.82% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $18.28 | +173.52% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.36 | +3,870.59% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $9.45 | +58.73% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $12.94 | +178.21% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $63.59 | +10.08% | 4 | May 29, 2024 |
Incyte
Oct 29, 2025
Reiterates: Hold
Price Target: $79 → $93
Current: $93.48
Upside: -0.51%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Buy
Price Target: $76 → $88
Current: $78.62
Upside: +11.93%
Scholar Rock Holding
Oct 20, 2025
Maintains: Buy
Price Target: $54 → $44
Current: $29.62
Upside: +48.55%
Viatris
Oct 15, 2025
Initiates: Buy
Price Target: $15
Current: $10.36
Upside: +44.79%
MBX Biosciences
Oct 15, 2025
Initiates: Buy
Price Target: $50
Current: $21.96
Upside: +127.69%
Madrigal Pharmaceuticals
Oct 15, 2025
Initiates: Buy
Price Target: $580
Current: $418.90
Upside: +38.46%
Terns Pharmaceuticals
Oct 15, 2025
Initiates: Buy
Price Target: $20
Current: $8.26
Upside: +142.13%
Kymera Therapeutics
Sep 30, 2025
Maintains: Buy
Price Target: $53 → $68
Current: $61.84
Upside: +9.96%
Regeneron Pharmaceuticals
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $651.80
Upside: +24.58%
Arvinas
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $10.14
Upside: +8.48%
Apr 29, 2025
Maintains: Buy
Price Target: $210 → $199
Current: $154.27
Upside: +28.99%
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $15.22
Upside: +64.26%
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $862.86
Upside: +20.30%
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $218.04
Upside: -0.48%
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $24.65
Upside: +29.82%
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $18.28
Upside: +173.52%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.36
Upside: +3,870.59%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $9.45
Upside: +58.73%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $12.94
Upside: +178.21%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $63.59
Upside: +10.08%